[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-mediated-inflammatory-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-mediated-inflammatory-diseases":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100552837","uk-cardiovascular-immune-mediated-inflammatory-diseases-cardio-imid-registry-study-100552837",false,"NCT06478277","UK CARDIOvascular Immune-Mediated Inflammatory Diseases (CARDIO-IMID) Registry Study","The UK CARDIOvascular Immune-Mediated Inflammatory Diseases (CARDIO-IMID) Registry","CARDIO-IMID","Inclusion Criteria:\n\n1. Written informed consent\n2. Diagnosis of an IMID by a rheumatologist with categorisation into one of the following:\n\n   i. IMID-'higher risk' CVD: individuals who have a risk of developing CVD (based on traditional risk factors and\u002For IMID-specific factors) but no history of CVD\n   1. Coronary artery disease (CAD): specifically, a high pre-test probability of CAD based on clinical risk factors (e.g. QRISK3 score ≥10%) and\u002For elevated biochemical markers (high-sensitivity C-reactive protein ≥2mg\u002FL and\u002For Lipoprotein(a) ≥70mg\u002FdL)\n   2. Myopericardial involvement: Specific IMID and\u002For cardiovascular indicators that place at increased risk e.g. autoantibody associations, presence of peripheral myositis or other major organ involvement; incidental raised serum cardiac biomarkers (troponin and\u002For NT-pro BNP), on routine testing\n\n      ii. Incident (new) IMID-CVD: Patients with IMID that present with a new history of CVD\n\n   \u003C!-- -->\n\n   1. ASCVD i. Major adverse cardiovascular events (MACE):\n\n      \\- Non-fatal myocardial infarction.\n\n      \\- Non-fatal stroke of any classification, including reversible focal neurologic\n\n      \\- Defects with imaging evidence of a new cerebral lesion consistent with ischemia or haemorrhage.\n\n      ii. Other cardiovascular events not accounted for in the MACE-3 composite 2)a)i:\n\n      \\- Hospitalization for unstable angina\n\n      \\- Coronary revascularization\n\n      \\- Hospitalization for heart failure\n\n      \\- Transient Ischemic Attack (TIA)\n\n      \\- Peripheral Vascular Disease (PVD)\n      * Deep vein thrombosis (VTE) and\u002For pulmonary embolism \\[PE\\].\n   2. Myopericardial involvement: as diagnosed by a cardiology specialist with 'tier 2' cardiovascular imaging and\u002For other clinical and biochemical criteria in line with usual care\n\n      iii. Established IMID-CVD\n\n   a) Patients with IMID and a history of past cardiovascular event as detailed in 2) a) above.\n\n   b) Patients with a known history of myopericardial involvement as defined above in 2) b)\n\nBiological sub-study inclusion criteria\n\n* There are no additional inclusion criteria for this sub-study\n\nExtended protocol standard CMR sub-study inclusion criteria.\n\n* Participants that receive a CMR scan as standard of care\n\nExclusion Criteria:\n\n1. Age less than 18 years\n2. Unable to give informed consent\n\nBiological sub-study exclusion criteria:\n\n\\- There are no additional exclusion criteria for this sub-study\n\nCMR sub-study exclusion criteria:\n\nStandard of care contraindications to:\n\n1. CMR: metal implant eg metal fragments in the eye, pacemaker; claustrophobia; inability to lie flat\n2. Magnetic Resonance Imaging (MRI) contrast: renal failure with estimated glomerular filtration rate (eGFR) \\\u003C30,","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational study is to develop a large, deeply characterised cohort that will be a platform for collaborative clinical and translational research into cardiovascular (CV) disease (CVD) and Immune-mediated-inflammatory-diseases (IMID). The main aim is to evaluate whether existing blood cardiac biomarkers predict adverse cardiovascular outcomes. The study will capture standard of care CV and associated health data (clinical, biochemistry\u002Fpathology and investigations) in patients across the IMIDs. Optional biological and\u002For imaging sub-studies will provide additional data and\u002For samples for associated analyses.",[26,27],"Cardiovascular Diseases","Immune-Mediated Inflammatory Diseases",[29,30,31],"Cardiovascular disease","Immune-mediated Inflammatory Diseases","Registry","RECRUITING","2026-02-04",{"date":35,"type":36},"2026-02-06","ACTUAL",{"date":33,"type":36},{"date":39,"type":21},"2028-08",{"name":41,"class":42},"University of Manchester","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":23,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100452498","registry-and-monitoring-of-immune-mediated-inflammatory-diseases-100452498","NCT05172284","Registry and Monitoring of ImmuNe-mediated Inflammatory Diseases","Registry and Monitoring of ImmuNe-mediated Inflammatory Diseases (IMIDs) REMIND Study","Inclusion Criteria:\n\n* Patients with a diagnosis of IMID.\n* Patients of any age, including minors.\n* Patients treated with approved medications for the condition in question and\u002For phototherapy.\n* Patients who agree to sign informed consent.\n\nExclusion Criteria:\n\n* Patients without a diagnosis of IMID.\n* Patients who do not consent to sign informed consent.",{"count":51,"type":21},2000,"15 Years","Formation of a registry of IMID patients to assess the evolution of resistance to conventional and target therapies. This aim is achieved by evaluating the achievement of PASI 50 and PASI 75 scores at week 16 from the start of treatment.",[55],"ImmuNe-Mediated Inflammatory Diseases","NOT_YET_RECRUITING","2022-01-10",{"date":59,"type":36},"2022-01-11",{"date":61,"type":21},"2022-02",{"date":63,"type":21},"2026-12",{"name":65,"class":42},"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio",1,"Immune Mediated Inflammatory Diseases"]